SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire &amp; inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

401JK Crypto is trending as its highly engaged community rallies behind its unique narrative to challenge traditional retirement systems. Recent excitement is driven by its appearance in a major exchange's presentation and upcoming marketing campaigns, with many holders showcasing strong conviction through staking and a shared belief in its long-term potential.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amid intense media M&A drama, as Paramount Skydance escalates its hostile bid for Warner Bros. Discovery, directly challenging Netflix's reported offer and raising concerns about potential regulatory hurdles. The ongoing uncertainty and perceived market "manipulation" are frustrating many investors, who are torn between fears of increased debt and the belief that the stock is "too cheap to ignore" ahead of its imminent earnings report.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Travere Therapeutics (TVTX) is highly volatile following its corporate update, which revealed the FDA requested additional clarification on clinical benefit for the FILSPARI label expansion in Focal Segmental Glomerulosclerosis (FSGS). This has triggered a significant sell-off as some investors anticipate a Complete Response Letter (CRL), while others view the drop as an overblown reaction, confidently buying the dip due to the company's strong existing IgA nephropathy (IgAN) drug sales and the potential for a first-ever FSGS therapy.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is actively discussed following strategic shifts, including a new "Meta Compute" initiative focused on scaling AI infrastructure through significant nuclear energy partnerships, alongside reported workforce reductions in its Reality Labs division. The community is sharply divided, with some investors questioning the large capital expenditure and perceived lack of immediate returns, while others view these investments as essential for long-term growth and AI leadership.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending following cautious 2026/2027 revenue guidance, largely driven by the anticipated impact of DefenCath's reimbursement shift in mid-2026, which triggered a sharp sell-off. The community is deeply divided, with many calling the plunge an "overreaction" and a buying opportunity given strong institutional ownership and pipeline potential. Others express frustration with management, viewing the guidance as conservative while anticipating future catalysts like the Kidney Care Access Protection Act and REZZAYO trial data.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is a trending topic amidst its J.P. Morgan conference presentation, the appointment of a Chief Commercial Officer, and recent publication of promising Phase 2 data for its obesity asset, VK2735. The community is debating whether these developments signal an imminent partnership or acquisition, leveraging the drug's "best-in-class" potential and significant market demand. However, some express frustration over perceived delays in FDA guidance and leadership's communication style, leading to varied sentiment on its competitive positioning in the lucrative metabolic therapies space.

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

Biodesix is trending sharply upward following its preliminary Q4 and full-year 2025 results, which reported strong revenue growth and reaffirmed positive adjusted EBITDA guidance. The community is actively discussing sustained momentum and further price appreciation, although some investors express caution regarding the company's cash position and potential future share dilution. This intense speculative interest, evidenced by massive trading volume, centers around the precision lung diagnostics firm.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo is trending following a CFO transition and preliminary Q4 results, which showed robust user growth but also a strategic focus on product investment over immediate financial performance. This has ignited a debate among investors, with some viewing the significant price decline as an overreaction and a long-term buying opportunity, while others worry about AI disruption and the stock's future valuation.

Monero

Monero (XMR) is experiencing strong upward momentum and outperforming Bitcoin, capturing significant attention amid ongoing global discussions around privacy regulations and potential bans on privacy tokens. The community is actively touting XMR as the 'true privacy king' and the original vision for crypto, contrasting its robust privacy features with perceived compromises in other major digital assets. This surge reflects a growing community interest in uncensorable, genuinely private transactions, particularly as competitor ZCash faces challenges and some view XMR as an essential alternative.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is heavily trending amid strong anticipation for its upcoming R2 launch event and the strategic appointment of a new Chief Customer Officer, signaling a significant push into a broader market. While some investors express bullish optimism, accumulating shares and touting its long-term potential against EV rivals, others remain skeptical, citing persistent cash burn and production execution concerns amidst recent analyst adjustments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sarepta Therapeutics (NASDAQ:SRPT) Shares Down 6.7% - What's Next?

Sarepta Therapeutics (NASDAQ:SRPT) Shares Down 6.7% - Time to Sell...

<ul class="summary-bullets"><li>Company CEO Doug Ingram said that the company “faced and overcame challenges in 2025.”</li><li>Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment.</li><li>Analysts on average expect the company to report total revenue of $2.12 billion for full year 2025.</li></ul> Shares of Sarepta Therapeutics Inc. (SRPT) sank 12% on Monday after the company said that it expects full year 2025 net product revenue of $1.86 billion, marking only slight growth from the $1.79 billion reported for full year 2024.Net product revenue refers to the company’s revenue from its products and does not include collaboration, contract manufacturing or royalty revenue.Analysts on average expect the company to report total revenue of $2.12 billion for full year 2025, according to data from Fiscal AI.<h2 class="st-heading-2">Results Breakdown</h2>Sarepta <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-reports-preliminary-fourth-quarter-and-full-year-2025">now sees</a> revenue from its top-selling gene therapy Elevidys for the full year to come to $898.7 million, including fourth quarter revenue of $110.4 million. The company said that the therapy’s revenue in the three months through the end of December was impacted by the year-end flu season and the need to reschedule six patient infusions into 2026.Revenue from the company’s other therapies for the full year is now expected at $965.6 million.Company CEO Doug Ingram said that the company “faced and overcame challenges in 2025.” “We have important initiatives in 2026 to continue the success of our approved therapies, particularly ELEVIDYS. We previously set a yearly sales floor for ELEVIDYS of $500.0 million. We reconfirm that floor and our intentions to exceed it,” Ingram said on Monday.The company further added that it had $953.8 million in preliminary cash, cash equivalents, restricted cash and investments as of 2025-end. The company will announce its full financial results in late February.<h2 class="st-heading-2">Elevidys Safety Concerns And Other Setbacks</h2>The preliminary numbers come in light of a challenging year for the company. Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment. Both non-ambulatory patients suffered from acute liver failure. DMD is a severe, inherited genetic disorder that causes progressive muscle weakness and degeneration.While Sarepta resumed shipments to DMD patients who can walk after a temporary pause, it is now developing a risk-mitigation approach for patients who cannot walk to resume shipments in the particular patient segment.In November, the company also announced that its two approved therapies Amondys 45 and Vyondys 53 in DMD failed in a key confirmatory trial aimed at a traditional full approval for the two. The company, however, continues to eye traditional approval based on the positive risk-benefits of the therapies and real-world evidence.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SRPT rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume increased from 'high’ to 'extremely high' levels.A Stocktwits user dismissed the sell-off and opined that the “Elevidys story isn’t broken.” They also noted that the company has enough cash to cover liabilities.<stembedurl>https://www.stocktwits.com/Initiator1/message/641562456</stembedurl>Another dismissed the selloff as a "minor setback."<stembedurl>https://www.stocktwits.com/ZzyzxResearch/message/641561010</stembedurl><a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> is down 82% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-lvlu-stock-surge-today/cmUaI8XR4Eo">Why Did LVLU Stock More Than Double Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sarepta Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

SRPT Stock Tumbles 12% On Lackluster Preliminary Revenue Numbers Due To Elevidys Safety Concerns

Sarepta now sees revenue from its top-selling gene therapy Elevidys for the full year to come to $898.7 million.

Equity

Sarepta now sees revenue from its top-selling gene therapy Elevidys for the full year to come to $898.7 million.


Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reports preliminary* fourth quarter and full-year 2025 net product revenues and cash, cash...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Hold" from Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) have been assigned an average rating of "Hold" from the thirty brokerages that are currently covering the stock, Marketbeat...

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntingtons Disease

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the submission of its clinical trial application (CTA) for Study SRP-1005-101...

Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare...

Sarepta Therapeutics, Inc. $SRPT Shares Acquired by Cwm LLC

Cwm LLC lifted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 4,033.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Dec. 31, 2025 that were previously approved by the Compensation...

Voya Investment Management LLC Trims Stock Holdings in Sarepta Therapeutics, Inc. $SRPT

Voya Investment Management LLC trimmed its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 99.5% during the third quarter, according to its most recent 13F filing with the SEC. The...

Assenagon Asset Management S.A. Sells 838,457 Shares of Sarepta Therapeutics, Inc. $SRPT

Assenagon Asset Management S.A. reduced its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 96.6% in the third quarter, according to the company in its most recent...

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Stocktwits

Stocktwits Polls

Despite recent stock drops, many users believe the company is deeply undervalued, fueling increasing speculation around a potential acquisition offer from a larger pharma. 

Traders are calling the stock's recent 11-14% drop an orchestrated 'scare tactic' or 'manipulation' by big players to acquire shares at lower prices, urging others to 'buy the dip'.

The J.P. Morgan conference is a major catalyst, with traders anticipating positive updates on siRNA pipeline programs for DM1 and FSHD, alongside regulatory clarity on PMOs.

Preliminary Q4 and full-year revenue, particularly for Elevidys, fell short of expectations and management's conservative 2026 outlook is causing concern despite a strong cash balance.

Discussion centers on the long-term impact of Duchenne Muscular Dystrophy (DMD) being added to the US newborn screening panel and future label expansion for Elevidys for broader patient groups.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$1.31	--	--	N/A
Q3 '25	-$0.73	-$1.80	-147.60%	MISSED
Q2 '25	$0.83	$1.89	127.08%	BEAT
Q1 '25	-$3.21	-$4.60	-43.44%	MISSED
Q4 '24	$1.92	$1.50	-21.87%	MISSED

SRPT
Sarepta Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest SRPT News

SRPTSarepta Therapeutics Inc